Why the study?
Does the Abbott AxSYM Cardiac Troponin I Assay provide valid analytic and clinical performance compared to the Stratus II assay for detecting myocardial injury?
Does the Abbott AxSYM Cardiac Troponin I Assay provide valid analytic and clinical performance compared to the Stratus II assay for detecting myocardial injury?
The Abbott AxSYM cTnI assay is a valid alternative to the Stratus II assay for detecting myocardial injury, though absolute values are 3-4 times higher.
No takes yet. Share an insight, caveat, or question.
Supports AxSYM with assay-specific cutoffs for AMI detection; leaves open prospective validation before routine adoption.
Elst et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: